These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26833481)

  • 1. STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population.
    Yamamoto K; Ioroi T; Kanaya K; Shinomiya K; Komoto S; Hirata S; Harada K; Watanabe A; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Miyake H; Fujisawa M; Hirai M
    Med Oncol; 2016 Mar; 33(3):24. PubMed ID: 26833481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.
    Yamamoto K; Shinomiya K; Ioroi T; Hirata S; Harada K; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Miyake H; Fujisawa M; Hirai M
    Target Oncol; 2016 Feb; 11(1):93-9. PubMed ID: 26300443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
    Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
    J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
    Watanabe A; Yamamoto K; Ioroi T; Hirata S; Harada K; Miyake H; Fujisawa M; Nakagawa T; Yano I; Hirai M
    Biol Pharm Bull; 2017; 40(4):458-464. PubMed ID: 28381801
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Yamamoto K; Ioroi T; Shinomiya K; Yoshida A; Harada K; Fujisawa M; Omura T; Ikemi Y; Nakagawa S; Yonezawa A; Ogawa O; Matsubara K; Iwamoto T; Nishikawa K; Hayashi S; Tohara D; Murakami Y; Motoshima T; Jono H; Yano I
    Oncol Res; 2022 May; 29(1):11-23. PubMed ID: 35016744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
    Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S;
    Eur Urol; 2013 Apr; 63(4):745-52. PubMed ID: 23063454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
    Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.
    Ivanyi P; Winkler T; Grosshennig A; Reuter C; Merseburger AS; Ganser A; Grünwald V
    World J Urol; 2010 Jun; 28(3):311-7. PubMed ID: 20443009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
    Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
    Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.
    Vanmechelen M; Lambrechts D; Van Brussel T; Verbiest A; Couchy G; Schöffski P; Dumez H; Debruyne PR; Lerut E; Machiels JP; Richard V; Albersen M; Verschaeve V; Oudard S; Méjean A; Wolter P; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Apr; 17(2):e235-e246. PubMed ID: 30527746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
    Numakura K; Tsuchiya N; Kagaya H; Takahashi M; Tsuruta H; Inoue T; Narita S; Huang M; Satoh S; Niioka T; Miura M; Habuchi T
    Anticancer Drugs; 2017 Jan; 28(1):97-103. PubMed ID: 27564227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.
    Zhao L; Zhang Q; Luan X; Huang X; Zhao S; Zhao H
    Int J Clin Exp Pathol; 2015; 8(2):2033-8. PubMed ID: 25973100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
    Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
    PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
    Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
    Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
    Cebrián A; Gómez Del Pulgar T; Méndez-Vidal MJ; Gonzálvez ML; Lainez N; Castellano D; García-Carbonero I; Esteban E; Sáez MI; Villatoro R; Suárez C; Carrato A; Munárriz-Ferrándiz J; Basterrechea L; García-Alonso M; González-Larriba JL; Perez-Valderrama B; Cruz-Jurado J; González Del Alba A; Moreno F; Reynés G; Rodríguez-Remírez M; Boni V; Mahillo-Fernández I; Martin Y; Viqueira A; García-Foncillas J
    Sci Rep; 2017 Jan; 7():41371. PubMed ID: 28117391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.
    Sławińska M; Zabłotna M; Gleń J; Lakomy J; Nowicki RJ; Sobjanek M
    Arch Dermatol Res; 2019 Nov; 311(9):697-704. PubMed ID: 31342143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population.
    Qin C; Cao Q; Li P; Ju X; Wang M; Chen J; Wu Y; Meng X; Zhu J; Zhang Z; Lu Q; Yin C
    PLoS One; 2012; 7(1):e28829. PubMed ID: 22295057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma?
    Masuda A; Kamai T; Abe H; Arai K; Yoshida K
    Biomed Res; 2009 Jun; 30(3):171-6. PubMed ID: 19574718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.